NCT04902040: Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: MSI-H
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Therapeutic Antibody, Immunotherapy, Radiation therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients must have microsatellite instability high (MSI-H) cancer; Patients must have progressed on previous anti-PD-1/PD-L1 treatment (e.g., pembrolizumab/Keytruda or atezolizumab/Tecentriq) +/- chemotherapy
Exclusions: Patients with unstable, symptomatic, or untreated central nervous system (brain) metastases that require steroids- see trial for details

Comments are closed.

Up ↑